Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells

BACKGROUND/AIMS: The treatment of chronic myeloid leukemia (CML) has achieved impressive success since the development of the Bcr-Abl tyrosine kinase inhibitor, imatinib mesylate. Nevertheless, resistance to imatinib has been observed, and a substantial number of patients need alternative treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dae Sik, Na, Yoo Jin, Kang, Myoung Hee, Yoon, Soo-Young, Choi, Chul Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773721/
https://www.ncbi.nlm.nih.gov/pubmed/26874514
http://dx.doi.org/10.3904/kjim.2015.024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773721/
https://www.ncbi.nlm.nih.gov/pubmed/26874514
http://dx.doi.org/10.3904/kjim.2015.024

Ejemplares similares